๐Ÿ‡บ๐Ÿ‡ธ FDA

Intelligence ยท Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors โ€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ€” searchable for business development and competitive intelligence.

12 results for โ€œSerumโ€ Clear

  1. ABIRATERONE ACETATE, DAROLUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, APALUTAMIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion, ENZALUTAMIDE

    Ningbo Cancer Hospital

    Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of โ‰ฅ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

    phase 3 small molecule active

    1 trial

  2. Bocouture, Placebo excipients (sucrose and human serum albumin) are reconstituted with sterile saline. Placebo vials will have identical appearance as the active product vials.

    Merz Therapeutics GmbH

    Moderate to Severe Platysma Prominence

    phase 3 small molecule active

    1 trial

  3. ECULIZUMAB , ECULIZUMAB

    Pari Pharma GmbH

    Adult patients with aHUS associated with HE and severe kidney involvement (needing dialysis or serum creatinine โ‰ฅ 354ฮผM)

    phase 3 small molecule active

    1 trial

  4. Rabies Vaccine (Serum-free Vero Cell), Freeze-dried

    Sinovac Research and Development Co.,

    Rabies

    phase 3 mab active

    2 trials

  5. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eligible for PA and comprising at least one of the following criteria: - Single tumour>3 cmโ‰ค 5cm or - multiple tumours (max 3 lesions โ‰ค 3cm) or - Single tumour between 2 and 3 cm with at least one of the following characteristic: โ€ข Serum AFP>100 ng/mL โ€ข Infiltrative form โ€ข Macro-trabecular subtype (if applicable)

    phase 2 small molecule active

    1 trial

  6. Purified Vero Rabies Vaccine Serum Free (VRVg)

    Sanofi Pasteur

    Rabies

    phase 2 mab completed

    1 trial

  7. X-vivo 15 (serum-free growth medium manufactured under gmp and commercially available from Lonza)

    Biogen

    Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment.

    phase 2 small molecule active

    1 trial

  8. A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoACP3 in patients with prostate cancer

    Philogen S.p.A.

    Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands

    phase 1 other active

    1 trial

  9. A Phase I study to evaluate the safety and dosimetry of imaging with 68Ga-OncoACP3 in prostate cancer.

    Philogen S.p.A.

    Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands

    phase 1 other active

    1 trial

  10. PMV via Puffhalerยฎ device

    Serum Life Science Europe GmbH

    Prophylaxis for the Measles Infection

    phase 1 mab completed

    1 trial

  11. HUMAN SERUM ALBUMIN, SODIUM CHLORIDE

    The George Institute

    descompensated hepatic cirrosis

    approved small molecule active

    1 trial

  12. Umbilical cord serum eyedrops

    Hospital Authority, Hong Kong

    Recurrent Corneal Erosion

    small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ€“3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources